Market Trends of Antibiotic Resistance Industry
The Complicated UTIs Segment is Expected to Hold a Major Share of the Market
The prevalence of complicated UTIs is expected to hold a major share in the market, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A complicated UTI is any urinary tract infection other than a simple UTI. Therefore, all urinary tract infections in immunocompromised patients, males, and those associated with fevers, stones, sepsis, urinary obstruction, catheters, or involving the kidneys are considered complicated infections.
The study published in May 2023 in the National Library of Medicine showed that 150 million cases of UTI occur globally per year, causing morbidity and mortality. Also, the article published in StatPearls and updated in November 2023 highlighted that in the United States, around 1.8% of hospitalizations are due to complicated UTIs. Such a high burden of disease creates the need for drugs for treatment, driving the growth of the segment.
In February 2024, Allecra Therapeutics received US Food and Drug Administration (FDA) approval for Exblifep. It is a cefepime/enmetazobactam that can be used to treat complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years of age and older.
Therefore, owing to factors such as the rising burden of complicated UTIs and increasing pipeline activities to treat complicated UTIs, the segment is expected to witness significant growth in the future.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to dominate the antibiotic resistance market over the forecast period. The market is growing in the region due to the high population resistant to antibiotics, high consumption of antibiotics, and increasing funding for research and development.
The increasing burden of antibiotic resistance in the region is expected to increase the demand for its therapy, which is expected to boost the market's growth over the forecast period. For instance, as per an article published in Global News in November 2022, in Canada, about 26% of infections that occur are resistant to first-line antibiotics. Resistance is expected to grow exponentially in the coming years, from 40% to 100% resistance to first-line antibiotics and antifungals by 2050. Thus, the increasing burden of antibiotic resistance in the country is expected to drive the growth of the antibiotic resistance market over the forecast period.
Increased funding and awards for AMR projects are expected to boost the market's growth in the region. For instance, in May 2024, the CDC invested USD 7.13 million in Minnesota to combat antimicrobial resistance. Thus, such initiatives are expected to boost the market's growth over the forecast period.
Therefore, the market is anticipated to witness growth in North America due to the factors mentioned above.
